广生堂 reported revenue of ¥0.22B for the period ended 2026-06-30, +5.4% year on year. Net income was ¥-0.08B, a -34.5% net margin on a 57.3% gross margin. The largest revenue line is 肝胆疾病药物 at 75% of the total. Free cash flow for the period was ¥-0.02B.
| Item | Amount | Y/Y |
|---|---|---|
| Revenue | ¥0.22B | +5.4% |
| Gross profit | ¥0.13B | — |
| Operating income | ¥-0.07B | — |
| Net income | ¥-0.08B | — |
| Gross margin | 57.3% | Net margin -34.5% |
| Revenue Q/Q | +23.6% | — |
| Segment | Revenue | Share |
|---|---|---|
| 肝胆疾病药物 | ¥0.17B | 75.5% |
| 肝病用药(医药商业) | ¥0.03B | 11.9% |
| 其他主营业务 | ¥0.02B | 11.2% |
| 其他(补充) | ¥0.00B | 1.4% |
| Item | Amount | % of revenue |
|---|---|---|
| Cost of revenue | ¥0.09B | 42.7% |
| R&D | ¥0.02B | 10.4% |
| SG&A | ¥0.14B | 64.3% |
| Tax & other | ¥0.01B | 3.5% |
| Item | Amount |
|---|---|
| Total assets | ¥1.34B |
| Total liabilities | ¥1.07B |
| Shareholders' equity | ¥0.27B |
| Equity / assets | 20.4% |
| Operating cash flow | ¥-0.01B |
| Capital expenditure | ¥0.01B |
| Free cash flow | ¥-0.02B |
| Cash conversion (OCF / net income) | 37% |
The Sankey chart shows how revenue splits into cost of revenue, R&D and SG&A, and what remains as profit — clean visuals for research decks and social posts.
清水源 ・ 鹏辉能源 ・ 美康生物 ・ 运达科技 ・ 鲍斯股份 ・ 金雷股份 ・ 双杰电气 ・ 康斯特 ・ 航天智造 ・ 全信股份 ・ 浩云科技 ・ 汉邦高科
Source: Eastmoney · This page shows public filing data only, not investment advice. · Browse all companies